NO843776L - Fremgangsmaate ved fremstilling av et terapeutisk virksomt ekstrakt. - Google Patents
Fremgangsmaate ved fremstilling av et terapeutisk virksomt ekstrakt.Info
- Publication number
- NO843776L NO843776L NO843776A NO843776A NO843776L NO 843776 L NO843776 L NO 843776L NO 843776 A NO843776 A NO 843776A NO 843776 A NO843776 A NO 843776A NO 843776 L NO843776 L NO 843776L
- Authority
- NO
- Norway
- Prior art keywords
- mixture
- approx
- pyridine
- oil
- purified
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims description 32
- 238000000034 method Methods 0.000 title claims description 19
- 238000002360 preparation method Methods 0.000 title claims description 9
- 230000001225 therapeutic effect Effects 0.000 title claims 2
- 239000000203 mixture Substances 0.000 claims description 35
- 239000002158 endotoxin Substances 0.000 claims description 32
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 28
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 13
- 239000000194 fatty acid Substances 0.000 claims description 13
- 229930195729 fatty acid Natural products 0.000 claims description 13
- 150000004665 fatty acids Chemical class 0.000 claims description 13
- 239000003921 oil Substances 0.000 claims description 10
- 244000005700 microbiome Species 0.000 claims description 9
- 208000020154 Acnes Diseases 0.000 claims description 5
- 239000003599 detergent Substances 0.000 claims description 5
- 241000186216 Corynebacterium Species 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 3
- NSFMUHNGROVPRE-UHFFFAOYSA-N 7-hexyloctadecane Chemical compound CCCCCCCCCCCC(CCCCCC)CCCCCC NSFMUHNGROVPRE-UHFFFAOYSA-N 0.000 claims description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims description 2
- 241000186363 Mycobacterium kansasii Species 0.000 claims description 2
- 241000187480 Mycobacterium smegmatis Species 0.000 claims description 2
- 241000187678 Nocardia asteroides Species 0.000 claims description 2
- 241000187563 Rhodococcus ruber Species 0.000 claims description 2
- 229940059904 light mineral oil Drugs 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 241000037164 Collema parvum Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000186366 Mycobacterium bovis Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 231100000284 endotoxic Toxicity 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000001373 regressive effect Effects 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000187481 Mycobacterium phlei Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607729 Salmonella enterica subsp. enterica serovar Abortus Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000007689 endotoxicity Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000025421 tumor of uterus Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/535,037 US4663306A (en) | 1983-09-23 | 1983-09-23 | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
Publications (1)
Publication Number | Publication Date |
---|---|
NO843776L true NO843776L (no) | 1985-03-25 |
Family
ID=24132594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO843776A NO843776L (no) | 1983-09-23 | 1984-09-20 | Fremgangsmaate ved fremstilling av et terapeutisk virksomt ekstrakt. |
Country Status (23)
Country | Link |
---|---|
US (1) | US4663306A (ko) |
JP (1) | JPS60120817A (ko) |
KR (1) | KR870000843B1 (ko) |
AT (1) | AT385659B (ko) |
AU (1) | AU566234B2 (ko) |
BE (1) | BE900650A (ko) |
CA (1) | CA1244765A (ko) |
CH (1) | CH664897A5 (ko) |
DE (1) | DE3434766C2 (ko) |
DK (1) | DK446684A (ko) |
ES (1) | ES8608872A1 (ko) |
FI (1) | FI843716L (ko) |
FR (1) | FR2552326B1 (ko) |
GB (1) | GB2149301B (ko) |
HU (1) | HU192585B (ko) |
IL (1) | IL73034A (ko) |
IN (1) | IN157240B (ko) |
IT (1) | IT1179444B (ko) |
NL (1) | NL8402902A (ko) |
NO (1) | NO843776L (ko) |
NZ (1) | NZ209635A (ko) |
SE (1) | SE8404707L (ko) |
ZA (1) | ZA847405B (ko) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4844894A (en) * | 1984-07-12 | 1989-07-04 | Ribi Immunochem Research Inc. | Method of inhibiting the onset of septicemia and endotoxemia |
US4806352A (en) * | 1986-04-15 | 1989-02-21 | Ribi Immunochem Research Inc. | Immunological lipid emulsion adjuvant |
US4877611A (en) * | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US4929604A (en) * | 1986-05-28 | 1990-05-29 | Board Of Regents, The University Of Texas System | Lipopolysaccharides of reduced toxicity and the production thereof |
ATE210989T1 (de) * | 1993-08-27 | 2002-01-15 | Vetrepharm Inc | Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung |
BE1007823A3 (fr) * | 1993-12-10 | 1995-10-31 | Anda Biolog Sa | Utilisation d'une composition comprenant au moins un antigene et/ou un ou plusieurs fragments de cet antigene pour l'obtention d'un medicament destine au traitement et/ou a la prevention du cancer. |
US6090385A (en) * | 1993-12-10 | 2000-07-18 | Maes; Hubert | Method of treating cancer |
US5976580A (en) | 1995-06-07 | 1999-11-02 | Novus International, Inc. | Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals |
DE19710255A1 (de) * | 1997-03-13 | 1998-09-17 | Henkel Ecolab Gmbh & Co Ohg | Verwendung einer Lösung zur Desaktivierung von Endotoxinen |
AU736450B2 (en) | 1997-08-05 | 2001-07-26 | Bioniche Urology Ip Inc. | Composition and method for regulating cell proliferation and cell death |
US6019985A (en) * | 1998-02-27 | 2000-02-01 | Munova Corporation | Immunostimulation methods for providing disease protection in poultry |
JP4447779B2 (ja) * | 1998-07-16 | 2010-04-07 | 市郎 東 | 細菌の菌体成分を有効成分とする癌免疫療法用製剤 |
CN101491536B (zh) * | 1999-12-13 | 2012-07-04 | 拜昂尼科生命科学有限公司 | 治疗用合成寡核苷酸 |
US7125858B2 (en) * | 1999-12-28 | 2006-10-24 | Bioniche Life Sciences Inc. | Hyaluronic acid in the treatment of cancer |
AU8582701A (en) * | 2000-07-11 | 2002-01-21 | Bayer Ag | Use of strains of the parapox ovis virus against organ fibrosis |
JP4176021B2 (ja) * | 2002-03-05 | 2008-11-05 | セルメディシン株式会社 | 固体化組織免疫アジュバント |
AU2003254792A1 (en) * | 2002-08-02 | 2004-02-23 | Sumitomo Pharmaceuticals Company, Limited | Bacterial cell wall skeleton component preparaion |
FR2848223B1 (fr) * | 2002-12-09 | 2005-02-25 | Centre Nat Rech Scient | Nouveau procede d'isolement des endotoxines. |
AU2003261624A1 (en) * | 2003-09-05 | 2005-03-29 | Shenyang Sunbellcom Bio-Pharmaceutical Co., Ltd. | A red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion |
CA2564180A1 (en) * | 2004-04-22 | 2005-11-03 | Dainippon Sumitomo Pharma Co., Ltd. | Pharmaceutical preparation containing bacterial cell wall skeleton component |
AU2014253791B2 (en) | 2013-04-18 | 2019-05-02 | Immune Design Corp. | GLA monotherapy for use in cancer treatment |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
CN106661543A (zh) | 2014-06-17 | 2017-05-10 | Xycrobe治疗公司 | 经遗传修饰的细菌和用于细菌的遗传修饰的方法 |
US11504404B2 (en) | 2016-02-24 | 2022-11-22 | Crown Laboratories, Inc. | Skin probiotic formulation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7308450A (ko) * | 1972-06-20 | 1973-12-27 | ||
FR2269962B1 (ko) * | 1974-05-06 | 1978-02-03 | Anvar | |
JPS58874B2 (ja) * | 1979-08-30 | 1983-01-08 | 株式会社 目黒研究所 | 糖蛋白wenac及びその製造法 |
US4436727A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4435386A (en) * | 1982-05-26 | 1984-03-06 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4436728A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
CA1206416A (en) * | 1982-06-30 | 1986-06-24 | John L. Cantrell | Pyridine soluble extract of a microorganism |
CA1206415A (en) * | 1982-06-30 | 1986-06-24 | John L. Cantrell | Pyridine soluble extract of a microorganism |
CA1209504A (en) * | 1982-06-30 | 1986-08-12 | John L. Cantrell | Pyridine soluble extract of a microorganism |
-
1983
- 1983-09-23 US US06/535,037 patent/US4663306A/en not_active Expired - Lifetime
-
1984
- 1984-09-19 DK DK446684A patent/DK446684A/da not_active Application Discontinuation
- 1984-09-20 SE SE8404707A patent/SE8404707L/xx not_active Application Discontinuation
- 1984-09-20 ZA ZA847405A patent/ZA847405B/xx unknown
- 1984-09-20 NO NO843776A patent/NO843776L/no unknown
- 1984-09-21 FR FR8414533A patent/FR2552326B1/fr not_active Expired
- 1984-09-21 AU AU33400/84A patent/AU566234B2/en not_active Ceased
- 1984-09-21 DE DE3434766A patent/DE3434766C2/de not_active Expired
- 1984-09-21 NL NL8402902A patent/NL8402902A/nl not_active Application Discontinuation
- 1984-09-21 CH CH4544/84A patent/CH664897A5/de not_active IP Right Cessation
- 1984-09-21 CA CA000463800A patent/CA1244765A/en not_active Expired
- 1984-09-21 GB GB08423993A patent/GB2149301B/en not_active Expired
- 1984-09-21 HU HU843585A patent/HU192585B/hu unknown
- 1984-09-21 BE BE0/213703A patent/BE900650A/fr not_active IP Right Cessation
- 1984-09-21 FI FI843716A patent/FI843716L/fi not_active Application Discontinuation
- 1984-09-21 ES ES536167A patent/ES8608872A1/es not_active Expired
- 1984-09-21 NZ NZ209635A patent/NZ209635A/xx unknown
- 1984-09-22 KR KR1019840005821A patent/KR870000843B1/ko active
- 1984-09-23 IL IL73034A patent/IL73034A/xx unknown
- 1984-09-24 IT IT48894/84A patent/IT1179444B/it active
- 1984-09-24 AT AT0302384A patent/AT385659B/de not_active IP Right Cessation
- 1984-09-25 IN IN677/CAL/84A patent/IN157240B/en unknown
- 1984-09-25 JP JP59198764A patent/JPS60120817A/ja active Granted
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4663306A (en) | Pyridine-soluble extract-refined detoxified endotoxin composition and use | |
US4436727A (en) | Refined detoxified endotoxin product | |
US4436728A (en) | Refined detoxified endotoxin product | |
US4435386A (en) | Refined detoxified endotoxin product | |
US4505900A (en) | Refined detoxified endotoxin product | |
US4505899A (en) | Refined detoxified endotoxin product | |
US4504473A (en) | Pyridine soluble extract of a microorganism | |
US4613504A (en) | Pyridine-soluble extracts of microorganisms | |
JPH0556326B2 (ko) | ||
JPS6254774B2 (ko) | ||
WO1994022462A1 (fr) | Complexe immunomodulateur anti-sida |